Accendra Health, Inc. (ACH) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 0.40%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 0.40% | Share-based compensation / revenue. Period ending 2026-06-30. $10.67M ÷ $2.65B × 100 ≈ 0.40% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 2.65B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 10.67M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 29.35M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $2.65B | $10.67M | $29.35M | (m) | (m) | 0.40% | (m) | (m) |
| 2026-03-31 | (m) | $2.72B | $11.54M | $24.79M | (m) | (m) | 0.42% | (m) | (m) |
| 2025-12-31 | (m) | $2.76B | $12.87M | $27.46M | $107.18M | (m) | 0.47% | 0.26× | Reported |
| 2025-09-30 | (m) | $10.77B | $24.89M | $-256.19M | $143.11M | (m) | 0.23% | -1.79× | Reported |
| 2025-06-30 | (m) | $10.76B | $28.22M | $-251.58M | $143.03M | (m) | 0.26% | -1.76× | Reported |
| 2025-03-31 | (m) | $10.72B | $26.90M | $-217.34M | $142.11M | (m) | 0.25% | -1.53× | Reported |
| 2024-12-31 | $13.00M | $10.70B | $26.84M | $-207.77M | $143.80M | 0.12% | 0.25% | -1.44× | Reported |
| 2024-09-30 | (m) | $10.66B | $25.08M | $114.22M | $144.97M | (m) | 0.24% | 0.79× | Reported |
| 2024-06-30 | (m) | $10.53B | $25.14M | $113.86M | $146.54M | (m) | 0.24% | 0.78× | Reported |
| 2024-03-31 | (m) | $10.42B | $23.62M | $104.40M | $151.37M | (m) | 0.23% | 0.69× | Reported |
| 2023-12-31 | $13.20M | $10.33B | $23.22M | $104.51M | $157.91M | 0.13% | 0.22% | 0.66× | Reported |
| 2023-09-30 | (m) | $10.23B | $22.64M | $-8.99M | $162.22M | (m) | 0.22% | -0.06× | Reported |
| 2023-06-30 | (m) | $10.13B | $21.46M | $27.41M | $163.96M | (m) | 0.21% | 0.17× | Reported |
| 2023-03-31 | (m) | $10.07B | $22.05M | $91.66M | $159.07M | (m) | 0.22% | 0.58× | Reported |
| 2022-12-31 | (m) | $9.96B | $20.99M | $142.91M | $128.89M | (m) | 0.21% | 1.11× | Reported |
| 2022-09-30 | (m) | $9.87B | $21.70M | $258.41M | $99.03M | (m) | 0.22% | 2.61× | Reported |
| 2022-06-30 | (m) | $9.88B | $23.19M | $261.04M | $70.74M | (m) | 0.23% | 3.69× | Reported |
| 2022-03-31 | (m) | $9.87B | $25.24M | $282.84M | $46.44M | (m) | 0.26% | 6.09× | Reported |
| 2021-12-31 | (m) | $9.79B | $25.02M | $368.47M | $48.09M | (m) | 0.26% | 7.66× | Reported |
| 2021-09-30 | (m) | $9.68B | $23.81M | $402.06M | $54.26M | (m) | 0.25% | 7.41× | Reported |
| 2021-06-30 | (m) | $9.37B | $25.24M | $414.74M | $63.66M | (m) | 0.27% | 6.51× | Reported |
| 2021-03-31 | (m) | $8.68B | $21.25M | $340.05M | $73.73M | (m) | 0.24% | 4.61× | Reported |
| 2020-12-31 | (m) | $8.48B | $20.01M | $204.12M | $83.40M | (m) | 0.24% | 2.45× | Reported |
| 2020-09-30 | (m) | $8.31B | $19.02M | $123.04M | $88.48M | (m) | 0.23% | 1.39× | Reported |
| 2020-06-30 | (m) | $8.41B | $15.52M | $73.60M | $91.56M | (m) | 0.18% | 0.80× | Reported |
| 2020-03-31 | (m) | $8.98B | $15.24M | $67.30M | $96.00M | (m) | 0.17% | 0.70× | Reported |
| 2019-12-31 | (m) | $9.21B | $15.80M | $73.15M | $98.11M | (m) | 0.17% | 0.75× | Reported |
| 2019-09-30 | (m) | $9.89B | $17.93M | $-209.55M | $105.09M | (m) | 0.18% | -1.99× | Reported |
| 2019-06-30 | (m) | $9.95B | $18.33M | $-213.50M | $104.98M | (m) | 0.18% | -2.03× | Reported |
| 2019-03-31 | (m) | $9.93B | $17.85M | $-401.70M | $95.87M | (m) | 0.18% | -4.19× | Reported |
| 2018-12-31 | (m) | $9.84B | $16.38M | $-392.17M | $77.02M | (m) | 0.17% | -5.09× | Reported |
| 2018-09-30 | (m) | $9.69B | $13.82M | $-135.25M | $62.21M | (m) | 0.14% | -2.17× | Reported |
| 2018-06-30 | (m) | $9.55B | $12.43M | $-126.94M | $47.12M | (m) | 0.13% | -2.69× | Reported |
| 2018-03-31 | (m) | $9.36B | $12.44M | $77.95M | $35.28M | (m) | 0.13% | 2.21× | Reported |
| 2017-12-31 | (m) | $9.32B | $11.91M | $89.25M | $31.77M | (m) | 0.13% | 2.81× | Reported |
| 2017-09-30 | (m) | $9.30B | $11.70M | $147.03M | $28.95M | (m) | 0.13% | 5.08× | Reported |
| 2017-06-30 | (m) | $9.38B | $11.69M | $170.93M | $26.98M | (m) | 0.12% | 6.33× | Reported |
| 2017-03-31 | (m) | $9.60B | $11.95M | $190.15M | $27.01M | (m) | 0.12% | 7.04× | Reported |
| 2016-12-31 | (m) | $9.72B | $12.04M | $199.60M | $27.06M | (m) | 0.12% | 7.38× | Reported |
| 2016-09-30 | (m) | $9.84B | $12.63M | $208.54M | $27.17M | (m) | 0.13% | 7.68× | Reported |
| 2016-06-30 | (m) | $9.90B | $12.23M | $208.55M | $27.14M | (m) | 0.12% | 7.68× | Reported |
| 2016-03-31 | (m) | $9.84B | $11.31M | $204.35M | $27.06M | (m) | 0.11% | 7.55× | Reported |
| 2015-12-31 | (m) | $9.77B | $11.31M | $200.36M | $27.15M | (m) | 0.12% | 7.38× | Reported |
| 2015-09-30 | (m) | $9.78B | $9.68M | $183.18M | $27.57M | (m) | 0.10% | 6.64× | Reported |
| 2015-06-30 | (m) | $9.69B | $9.06M | $164.98M | $25.13M | (m) | 0.09% | 6.56× | Reported |
| 2015-03-31 | (m) | $9.57B | $8.16M | $154.23M | $21.80M | (m) | 0.09% | 7.08× | Reported |
| 2014-12-31 | (m) | $9.44B | $8.21M | $159.54M | $18.16M | (m) | 0.09% | 8.78× | Reported |
| 2014-09-30 | (m) | $9.27B | $7.36M | $169.70M | $14.16M | (m) | 0.08% | 11.99× | Reported |
| 2014-06-30 | (m) | $9.15B | $7.12M | $183.54M | $13.24M | (m) | 0.08% | 13.86× | Reported |
| 2014-03-31 | (m) | $9.08B | $7.11M | $196.48M | $13.14M | (m) | 0.08% | 14.95× | Reported |
| 2013-12-31 | (m) | $9.07B | $6.38M | $198.08M | $13.10M | (m) | 0.07% | 15.12× | Reported |
| 2013-09-30 | (m) | $9.17B | $6.01M | $192.19M | $13.26M | (m) | 0.07% | 14.50× | Reported |
| 2013-06-30 | (m) | $9.05B | $5.02M | $189.64M | $12.93M | (m) | 0.06% | 14.66× | Reported |
| 2013-03-31 | (m) | $8.97B | $5.22M | $192.76M | $13.17M | (m) | 0.06% | 14.63× | Reported |
| 2012-12-31 | (m) | $8.91B | $5.70M | $196.75M | $13.40M | (m) | 0.06% | 14.69× | Reported |
| 2012-09-30 | (m) | $8.78B | $6.18M | $194.73M | $13.49M | (m) | 0.07% | 14.43× | Reported |
| 2012-06-30 | (m) | $8.78B | $6.22M | $206.53M | $13.85M | (m) | 0.07% | 14.91× | Reported |
| 2012-03-31 | (m) | $8.72B | $5.04M | $204.39M | $13.39M | (m) | 0.06% | 15.27× | Reported |
| 2011-12-31 | (m) | $8.63B | $5.67M | $203.51M | $13.68M | (m) | 0.07% | 14.87× | Reported |
| 2011-09-30 | (m) | $8.50B | $5.24M | $199.81M | $13.92M | (m) | 0.06% | 14.35× | Reported |
| 2011-06-30 | (m) | $8.39B | $5.31M | $196.66M | $14.26M | (m) | 0.06% | 13.79× | Reported |
| 2011-03-31 | (m) | $8.28B | $6.41M | $197.78M | $14.74M | (m) | 0.08% | 13.42× | Reported |
| 2010-12-31 | (m) | $8.12B | $6.36M | $195.94M | $14.32M | (m) | 0.08% | 13.68× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $8.04B | $7.04M | $201.28M | $13.03M | (m) | 0.09% | 15.45× | Reported |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $7.24B | $7.56M | $180.72M | $16.00M | (m) | 0.10% | 11.30× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HENRY SCHEIN INC (HSIC) | United States | $9.536B | 23.59 |